Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Association of resistin and adiponectin with different clinical blood pressure phenotypes

Journal of Human Hypertension volume 25, pages 38–46 (2011)Cite this article

Subjects

Abstract

We investigated whether the resistin (Res) and adiponectin (Adp) levels are associated with different clinical blood pressure (BP) phenotypes. Among 465 consecutive never-treated white subjects, we excluded those with diabetes mellitus; impaired glucose metabolism; history of any cardiovascular disease or other concurrent medical condition; secondary hypertension; ongoing vasoactive treatment. Three separate clinic BP measurements and ambulatory BP monitoring were implemented to divide 328 subjects (aged 48±6 years; 172 males) into hypertensives (n=105), masked hypertensives (n=41), white-coat hypertensives (n=52) and normotensives (n=130). Participants underwent echocardiography and oral glucose tolerance testing, whereas, from fasting venous blood samples metabolic profile, plasma Res and Adp levels were assessed. Hypertensives and masked hypertensives showed higher log(10)(Res) and lower log(10)(Adp) levels compared with normotensives, whereas white-coat hypertensives had similar levels of these adipokines compared with normotensives. Common correlates for both of the adipokines were 24-h systolic BP, standing/sitting difference of both diastolic BP and heart rate, and waist circumference. Hypertensive and masked hypertensive compared with normotensive phenotype were independently associated with log(10)(Res) with odds ratios of 1.24 (1.08–1.44), and 1.16 (1.09–1.34) and log(10)(Adp) with 0.74 (0.65–0.87), and 0.81 (0.67–0.95), respectively. Increased Res and decreased Adp plasma levels are associated with out-of-clinic hypertension, whereas they did not determine white-coat hypertension.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Calle EE, Chun MJ, Petrelli JM, Rodrigues C, Heath CDW . Body mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341: 1097–1105.

    Article  CAS  Google Scholar 

  2. Lavie CJ, Milani RV, Ventura HO . Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53: 1925–1932.

    Article  Google Scholar 

  3. Fantuzzi G, Mazzone T . Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol 2007; 27: 996–1003.

    Article  CAS  Google Scholar 

  4. Helibronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese and obese diabetic subjects. J Clin Endocrinol Metab 2004; 4: 1844–1848.

    Article  Google Scholar 

  5. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288–1295.

    Article  CAS  Google Scholar 

  6. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD et al. Resistin promotes endothelial activation: further evidence of adipokine-endothelial interaction. Circulation 2003; 108: 307–312.

    Google Scholar 

  7. Tan KC, Xu A, Chow WS, Lam MC, Ai VH, Tam SC et al. Hypoadinonectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 2004; 89: 765–769.

    Article  CAS  Google Scholar 

  8. Pang S, Le Y . Role of resistin in inflammation and inflammation-related diseases. Cellular Mol Immunol 2006; 3: 29–34.

    CAS  Google Scholar 

  9. Krenning G, Moonen JR, Harmsen MC . Pleiotropism of adiponectin: inflammation, neovascularization, and fibrosis. Circ Res 2009; 104: 1029–1031.

    Article  CAS  Google Scholar 

  10. Tsioufis C, Dimitriadis K, Selima M, Thomopoulos C, Mihas C, Skiadas I et al. Low-grade inflammation and hypoadiponectinemia have an additive detrimental effect on aortic stiffness in essential hypertensive subjects. Eur Heart J 2007; 28: 1162–1169.

    Article  CAS  Google Scholar 

  11. Furuhashi M, Ura N, Hagashiura K, Murakami H, Shimamoto K . Circulating resistin levels in essential hypertension. Clin Endocrinol 2003; 59: 507–510.

    Article  CAS  Google Scholar 

  12. Takata Y, Osawa H, Kurata M, Korokawa M, Yamauki J, Ochi M et al. Hyperresistinemia is associated with coexistence of diabetes and hypertension. Hypertension 2008; 51 (Part 2): 534–539.

    Article  CAS  Google Scholar 

  13. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318–1323.

    Article  CAS  Google Scholar 

  14. Bobrie G, Clerson P, Menard J, Postel-Vinay N, Chatelier G, Plouin P . Masked hypertension: a systematic review. J Hypertens 2008; 26: 1715–1725.

    Article  CAS  Google Scholar 

  15. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793–801.

    Article  CAS  Google Scholar 

  16. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J et al. Prognosis of masked hypertension and white-coat hypertension detected by 24-h ambulatory blood pressure monitoring: 10-year follow-up from the Ohasama study. J Am Coll Cardiol 2005; 46: 508–515.

    Article  Google Scholar 

  17. Mancia G, Facchetti R, Bombelli M, Grassi S, Sega R . Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006; 47: 846–853.

    Article  CAS  Google Scholar 

  18. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 2007; 25: 1751–1762.

    Article  CAS  Google Scholar 

  19. O' Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T et al. European Society of Hypertension Working Group on Blood Pressure Monitoring. Practice guidelines of the European Society of Hypertension for clinic, ambulatory, and self blood pressure measurement. J Hypertens 2005; 23: 697–701.

    Article  CAS  Google Scholar 

  20. Tsioufis C, Stefanadis C, Antoniadis D, Kallikazaros I, Zambaras P, Pitsavos C et al. Absence of any significant effects of circadian blood pressure variations on carotid artery elastic properties in essential hypertensive subjects. J Hum Hypertens 2000; 14: 813–818.

    Article  CAS  Google Scholar 

  21. Schiller NB, Shah PM, Crawford M, De Maria A, Devereux R, Feigenbaum H et al. Recommendations for quantitation of left ventricular dimensions by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on quantization of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989; 2: 358–367.

    Article  CAS  Google Scholar 

  22. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification. Eur J Echocardiog 2006; 7: 79–108.

    Article  Google Scholar 

  23. Thomopoulos C, Papadopoulos DP, Papazachou O, Bratsas A, Massias S, Anastasiadis A et al. Free leptin is associated with masked hypertension in nonobese subjects: a cross-sectional study. Hypertension 2009; 53: 965–972.

    Article  CAS  Google Scholar 

  24. Papadopoulos DP, Makris TK, Krespi PG, Poulakou M, Stavroulakis G, Hatzizacharias AN et al. Adiponectin and resistin plasma levels in healthy individuals with prehypertension. J Clin Hypertens 2005; 7: 729–733.

    Article  CAS  Google Scholar 

  25. Papadopoulos DP, Perrea D, Thomopoulos C, Sanidas E, Daskalaki M, Papazachou U et al. Masked hypertension and atherogenesis: the impact on adiponectin and resistin plasma levels. J Clin Hypertens 2009; 11: 61–65.

    Article  CAS  Google Scholar 

  26. Papadopoulos DP, Makris TK, Perrea D, Papazachou O, Daskalaki M, Sanidas E et al. Adiponectin, insulin and resistin plasma levels in young healthy offspring of patients with essential hypertension. Blood Press 2008; 17: 50–54.

    Article  CAS  Google Scholar 

  27. Ohmori R, Momiyama Y, Kato R, Tanaguchi H, Ogura M, Ayaori M et al. Associations between serum resistin levels and insulin resistance, inflammation and coronary artery disease. J Am Coll Cardiol 2005; 46: 379–380.

    Article  Google Scholar 

  28. Kawanami D, Maemura K, Takeda N, Harrada T, Nojiri T, Imai Y et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004; 314: 415–419.

    Article  CAS  Google Scholar 

  29. Gentile MT, Vecchione C, Marino G, Aretini A, Di Pardo A, Antenucci G et al. Resistin impairs insulin-evoked vasodilation. Diabetes 2008; 57: 577–583.

    Article  CAS  Google Scholar 

  30. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277: 25863–25866.

    Article  CAS  Google Scholar 

  31. Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagetani H et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42: 231–234.

    Article  CAS  Google Scholar 

  32. Ouedraogo R, Gong Y, Berzins B, Wu X, Mahadev K, Hough K et al. Adiponectin deficiency increases leukocyte-endothelial interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 2007; 117: 1718–1726.

    Article  CAS  Google Scholar 

  33. Ran J, Hirano T, Fukui T, Saito K, Kageyama H, Okada K et al. Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism 2006; 55: 478–488.

    Article  CAS  Google Scholar 

  34. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76–81.

    Article  CAS  Google Scholar 

  35. Tanida M, Shen J, Horii Y, Matsuda M, Kihara S, Funahashi T et al. Effects of adiponectin on the renal sympathetic nerve activity and blood pressure in rats. Exp Biol Med (Maywood) 2007; 232: 390–397.

    CAS  Google Scholar 

  36. Rahmouni K, Correia LG, Haynes WG, Mark AL . Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005; 45: 9–14.

    Article  CAS  Google Scholar 

  37. Shin HJ, Park S, Yoon SJ, Cho DK, Kim JS, Ko YG et al. Association between serum resistin and carotid intima media thickness in hypertensive patients. Int J Cardiol 2008; 125: 79–84.

    Article  Google Scholar 

  38. Dimitriadis K, Tsioufis C, Selima M, Tsiachris D, Miliou A, Kasiakogias A et al. Independent association of circulating resistin with glomeular filtration rate in the early stages of essential hypertension. J Hum Hypertens 2009; 23: 668–673.

    Article  CAS  Google Scholar 

  39. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N et al. Coronary artery disease: association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85–89.

    Article  CAS  Google Scholar 

  40. Kim M, Oh JK, Sakata S, Liang I, Park W, Hajjar RJ et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 2008; 45: 270–280.

    Article  CAS  Google Scholar 

  41. Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Friz HP et al. Lon-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension 2009; 54: 226–232.

    Article  CAS  Google Scholar 

  42. Mulè G, Nardi E, Cottone S, Cusimano P, Incalcaterra F, Palermo A et al. Metabolic syndrome in subjects with white-coat hypertension: impact on left ventricular structure and function. J Hum Hypertens 2007; 21: 854–860.

    Article  Google Scholar 

  43. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C . Definition of metabolic syndrome: Report of the National Heart, Lung and Blood Institute/American Heart Association Conference on Scientific Issues related to definition. Circulation 2004; 109: 433–438.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Elena Venizelou General and Maternity Hospital, Athens, Greece

    C Thomopoulos, M Daskalaki, O Papazachou, N Rodolakis, A Bratsas & T Makris

  2. Department of Cardiology, Laiko General Hospital, Athens, Greece

    D P Papadopoulos

  3. Department of Cardiology, Sismanoglion General Hospital, Athens, Greece

    M V Papavasileiou

  4. Department of Experimental Surgery and Surgical Research, Athens School of Medicine, Athens, Greece

    D Perrea

Authors
  1. C Thomopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Daskalaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O Papazachou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Rodolakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Bratsas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D P Papadopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M V Papavasileiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Perrea
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T Makris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Thomopoulos.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thomopoulos, C., Daskalaki, M., Papazachou, O. et al. Association of resistin and adiponectin with different clinical blood pressure phenotypes. J Hum Hypertens 25, 38–46 (2011). https://doi.org/10.1038/jhh.2010.22

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2010.22

Keywords

This article is cited by

Search

Advanced search

Quick links